adalimumab (Humira)

following an abbreviated submission

adalimumab (Humira®) is accepted for restricted use within NHS Scotland

Indication under review: for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy.

SMC restriction: use within specialist rheumatology services (including those working within the network for paediatric rheumatology).

Treatment of paediatric patients with adalimumab resulted in clinically relevant improvements in the number of active joints with arthritis compared with placebo at 12 weeks. 

Adalimumab has previously been accepted for restricted use within NHS Scotland in combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 2 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs).